Psoriasis Drugs Market Size To Reach $39.11 billion By 2030

Psoriasis Drugs Market Growth & Trends

The global psoriasis drugs market size is anticipated to reach USD 39.11 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.8% from 2024 to 2030. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

 Request a free sample copy or view report summary: Psoriasis Drugs Market Report

Psoriasis Drugs Market Report Highlights

• Tumor necrosis factor inhibitors dominated the market and accounted for a share of 41.0% in 2023 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.

• The biologics segment dominated the market in 2023 with a share of 46.3% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.

• The topical segment is projected to grow at a CAGR of 10.4% over the forecast period as many people opt for non-surgical procedures and formulations are designed to enhance the efficacy of topical remedies.

• The hospital pharmacies segment accounted for a leading share of 41.5% in 2023 owing to hospitals offering expensive, specialized treatments such as biologics and advanced systemic therapies.

• North America psoriasis drugs market dominated the global market with a share of 38.4% in 2023 due to its advanced healthcare system that enables patients to receive early diagnosis and complete treatment.

Psoriasis Drugs Market Segmentation

Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region.

Psoriasis Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)

• Tumor Necrosis Factor Inhibitors

• Interleukin Inhibitors

• Vitamin D Analogues

• Corticosteriods

• Others

Psoriasis Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Topicals

• Systemic

• Biologics

Psoriasis Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

• Topical

Psoriasis Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Psoriasis Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players in the Psoriasis Drugs Market

• AbbVie Inc.

• Amgen Inc.

• Johnson & Johnson Services, Inc.

• Novartis AG

• Eli Lilly and Company

• AstraZeneca

• Celgene Corporation

• UCB S.A.

• Merck

• Boehringer Ingelheim International GmbH